Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more

Recent & Breaking News (NYSEAM:TOVX)

Synthetic Biologics and Enterome Bioscience Collaborate on Microbiome Research to Support Synthetic Biologics' C. difficile Program

PR Newswire June 10, 2014

Synthetic Biologics to Present at the 3rd Annual Marcum LLP MicroCap Conference

PR Newswire May 20, 2014

Synthetic Biologics Reports First Quarter 2014 Financial Results and Operational Highlights

PR Newswire May 15, 2014

Synthetic Biologics to Report First Quarter 2014 Financial Results

PR Newswire May 9, 2014

Synthetic Biologics Announces Recent International Patents that Bolster its C. difficile Program

PR Newswire May 8, 2014

Synthetic Biologics to Discuss Phase II Results of Oral Estriol Candidate Trimesta(TM) for Relapsing-Remitting Multiple Sclerosis in Women

PR Newswire April 30, 2014

Synthetic Biologics Reports UCLA Announcement of Preliminary Positive Topline Efficacy and Safety Results from Investigator-Led Phase II Study of Trimesta(TM) for Relapsing-Remitting Multiple Sclerosis

PR Newswire April 29, 2014

Synthetic Biologics' Reports Preclinical Data to Support Clinical Development of Novel Pertussis Therapeutic

PR Newswire April 23, 2014

Synthetic Biologics Appoints Mark Pimentel, M.D., Chairman of New Irritable Bowel Syndrome Clinical Advisory Board

PR Newswire April 14, 2014

Synthetic Biologics Reports Year End 2013 Financial Results and Operational Update

PR Newswire March 31, 2014

Synthetic Biologics to Report Year End 2013 Financial Results

PR Newswire March 25, 2014

Synthetic Biologics Announces Issuance of U.S. Patent Adding Another Layer of Protection for the Use of Oral Estriol Candidate, Trimesta(TM), for Multiple Sclerosis

PR Newswire March 10, 2014

Synthetic Biologics to Present at the 26th Annual ROTH Conference

PR Newswire March 5, 2014

Synthetic Biologics' Board of Directors Accepts Resignation of Long-Standing Founder and Board Member

PR Newswire February 26, 2014

Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity

PR Newswire February 13, 2014

Synthetic Biologics Announces Rhonda Voskuhl, M.D., to Present Trimesta(TM) Phase II Multiple Sclerosis Clinical Trial Results at the 2014 AAN Annual Meeting

PR Newswire February 10, 2014

Synthetic Biologics to Present at the 2014 BIO CEO & Investor Conference

PR Newswire February 4, 2014

Synthetic Biologics Strengthens Clinical & Regulatory Team to Support Expanding Pipeline of Infectious Disease Programs

PR Newswire January 27, 2014

Synthetic Biologics to Present at the Biotech Showcase(TM) 2014 Conference

PR Newswire January 8, 2014

Synthetic Biologics to Present at the 7th Annual OneMedForum San Francisco 2014 Conference

PR Newswire January 8, 2014